- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01794000
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The submission database was validated for data reported through the data cutoff date for the submission database lock (SDBL). The SDBL data cutoff was 17 July 2015 for all participants except for 2 in the youngest age group, for whom the SDBL data cutoff occurred on 08 August 2015. The data cutoff date for SDBL corresponds to the primary completion date for the study. The SDBL occurred on 31 August 2015.
The study was stopped following SDBL and review of the topline information indicated that the primary and secondary efficacy endpoints were not met. Subsequently, the Sponsor requested that participants discontinue study drug immediately and that discontinuation visits for all active study participants be conducted as soon as feasible.
After the data cutoff date for SDBL, the Sponsor continued to collect safety data through the final participants contact; some additional efficacy data were collected through the final visit. The last patient visit (LPV) occurred on 17 December 2015, which corresponds to the study completion date and led to the planned supplemental database lock (PSDBL) on 22 January 2016. This supplemental data base was originally designed to capture additional blinded and randomized information to enhance safety data for labeling should the study have been positive.
The safety information contained in this record reflects the entire safety information and reflects the information from the supplemental data base lock in January of 2016. The efficacy information contained in this record reflects the information collected through primary completion date in the submission database. Primary analyses of the major efficacy objectives were repeated using the entire double-blind period data from the PSDBL and did not change the original conclusions and were consistent with the results from the original efficacy analyses included in the SDBL.
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Brussel, Belgia, 1200
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Montegnee, Belgia, 4420
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Rio De Janeiro, Brasil, 20211-030
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Abu Dhabi, De forente arabiske emirater
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Alexandria, Egypt, 21131
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Cairo, Egypt, 11566
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Fayoum, Egypt, 63514
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Ismailia, Egypt
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Mansoura, Egypt, 35516
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Zagazig, Egypt, 44519
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
California
-
Oakland, California, Forente stater, 94609
- Children's Hospital of Oakland
-
Palo Alto, California, Forente stater, 94304
- Stanford Univ Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06106
- Connecticut Children's Medical Center
-
-
District of Columbia
-
Washington, District of Columbia, Forente stater, 20060
- Howard University Hospital
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Emory University
-
Savannah, Georgia, Forente stater, 31404
- Memorial Health University Medical Center
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Ann & Robert H Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Boston Children's Hospital
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48201
- Childrens Hospital of Michigan
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64108
- Children's Mercy Hospital
-
-
New York
-
Bronx, New York, Forente stater, 10467
- Albert Einstein College Of Medicine
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- University of NC at Chapel Hill School of Medicine
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Childrens Hospital Medical Center
-
Cleveland, Ohio, Forente stater, 44106
- Rainbow Babies and Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19134
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Forente stater, 19134
- St Christophers Hospital For Children
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Childrens Hospital of Pittsburgh
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, Forente stater, 38105
- St Jude Childrens Research Hospital
-
-
Washington
-
Tacoma, Washington, Forente stater, 98405
- Mary Bridge Children's Hospital and Health Center
-
-
-
-
-
Agogo, Ghana
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Korle Bu, Ghana
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Genova, Italia, 16128
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Modena, Italia, 40124
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Monza, Italia, 20900
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Padova, Italia, 35138
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Verona, Italia, 37126
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Busia, Kenya, 40100
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Kisumu, Kenya
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Kombewa, Kenya
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Nairobi, Kenya
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Beirut, Libanon, 5244
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Muscat, Oman, 123
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Jeddah, Saudi-Arabia, 21859
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
London, Storbritannia, SE1 7EH
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Manchester, Storbritannia, M13 9WL
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
London
-
Tooting, London, Storbritannia, SW17 0QT
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
-
-
-
Balcali Adana, Tyrkia, 01330
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Mersin, Tyrkia, 33079
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Have SCD [homozygous sickle cell (HbSS) or hemoglobin (HbS) Beta^0 thalassemia]
- Are participants with SCD who have had ≥2 episodes of vaso-occlusive crisis (VOC) in the past year
- Have a body weight ≥19 kilograms (kg) and are ≥2 and <18 years of age, inclusive at the time of screening
- If participants are ≥2 and ≤16 years of age, must have had a transcranial Doppler within the last year
Exclusion Criteria:
- History of: transient ischemic attack (TIA)/ ischemic or hemorrhagic stroke, severe head trauma, intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm
- History of abnormal or conditional [velocity in middle or anterior cerebral, or internal carotid artery ≥170 centimeter per second (cm/sec)] transcranial Doppler within the last year
- History of, or are undergoing treatment with, chronic red blood cell (RBC) transfusion therapy
- Are at an increased risk for bleeding complications
- Are receiving chronic treatment with nonsteroidal anti-inflammatory drug (NSAID)s and cannot be switched to another analgesic
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Prasugrel
Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument.
This corresponds to a range of platelet inhibition of approximately 30% to 60%.
The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.
|
Administrert oralt
Andre navn:
|
Placebo komparator: Placebo
Participants in this treatment group will receive daily orally administered placebo and will follow visit schedule identical to that in the active treatment group.
|
Administreres oralt
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of Vaso-Occlusive Crisis (VOC) Events Per Participant Per Year (Rate of VOC)
Tidsramme: Randomization through 24 Months
|
The VOC is a composite endpoint of painful crisis or acute chest syndrome.
Events that occurred within 7 days from the prior event onset date were not counted as a new episode.
Data collected through the primary completion date reported below.
|
Randomization through 24 Months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Monthly Rate of Days With Pain
Tidsramme: Randomization through 9 Months
|
Monthly rate of days with pain was measured through participant diaries using a modified version of the Faces Pain Scale-Revised (FPS-R).
Each day participants selected the face on the scale that reflected their worst pain related to sickle cell disease (SCD) on that day.
This pain scale contains six faces corresponding to the pain intensity of 0, 2, 4, 6, 8 or 10, in which 0 denotes no pain and 10 denotes the worst pain possible.
Any day the participant selected a face other than face 0 was considered a day with pain.
Monthly rate of days with pain was calculated for each participant by summing the number of days reported with any pain divided by the number of non-missing diary entries completed in the month.
A month was defined as 4 weeks (28 days).The monthly rate was set to missing if there were more than 14 missing entries for the FPS-R in a specific month.
Data collected through the primary completion date are present below.
|
Randomization through 9 Months
|
Monthly Mean in Faces Pain Scale-Revised Score
Tidsramme: Randomization through 9 Months
|
Each day participants selected the face on the FPS-R scale that reflected their worst pain related to sickle cell disease (SCD) on that day.
Monthly mean in FPS-R score was calculated for each participant by summing the FPS-R score divided by the number of non-missing diary entries completed in the month.
This pain scale contains six faces corresponding to the pain intensity of 0, 2, 4, 6, 8 or 10, in which 0 denotes no pain and 10 denotes the worst pain possible.
A month was defined as 4 weeks (28 days).
The monthly mean in FPS-R score was set to missing if there were more than 14 missing entries for the FPS-R in a specific month.
Data collected through the primary completion date are presented below.
|
Randomization through 9 Months
|
Number of Painful Crisis Events Per Participant Per Year (Rate of Painful Crisis)
Tidsramme: Randomization through 24 Months
|
A painful crisis is defined as an onset of moderate to severe pain that lasts at least 2 hours for which there is no explanation other than vaso-occlusion and which requires therapy with oral or parenteral opioids, ketorolac, or other analgesics prescribed by a health care provider (HCP) in a medical setting such as a hospital, clinic, emergency room visit, or telephone management.
The painful crisis that occurred within 7 days from the prior event onset date was not counted as a new episode.
Data collected through the primary completion date are presented below.
|
Randomization through 24 Months
|
Number of Hospitalizations for VOC Per Participant Per Year (Rate of Hospitalizations)
Tidsramme: Randomization through 24 Months
|
Hospitalization that occurred within 7 days of the prior event onset date were not counted as a new episode.
Data collected through the primary completion date are presented below.
|
Randomization through 24 Months
|
Number of Acute Chest Syndrome Per Participant Per Year (Rate of Acute Chest Syndrome)
Tidsramme: Randomization through 24 Months
|
Acute chest syndrome was defined as an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray.
Acute chest syndrome that occurred within 7 days of the prior event onset date was not counted as a new episode.
Data collected through the primary completion date are presented below.
|
Randomization through 24 Months
|
Number of Red Blood Cell (RBC) Transfusions Due to Sickle Cell Disease (SCD) Per Participant Per Year (Rate of RBC Transfusions)
Tidsramme: Randomization through 24 Months
|
RBC transfusions that occurred within 7 days of the prior event onset date were not counted as a new episode.
Data collected through the primary completion date are presented below.
|
Randomization through 24 Months
|
Monthly Rate of Days of Analgesic Use
Tidsramme: Randomization through 9 Months
|
Monthly rate of days of analgesic use was measured through participant diaries and was calculated for each participant by summing the number of days they reported analgesic use divided by the number of diary entries completed in the month.
A month was defined as 4 weeks (28 days).
The monthly rate was set to missing if there were more than 14 missing entries for analgesic use in a specific month.
Data collected through the primary completion date are presented below.
|
Randomization through 9 Months
|
Quarterly Rate of School Absence Due to Sickle Cell Pain
Tidsramme: Randomization through 9 Months
|
Quarterly rate of school absence due to sickle cell pain was measured through participant diaries and was calculated for each participant by summing the number of days with school absence due to sickle cell pain divided by the number of school dates in the quarter.
A quarter was defined as 12 weeks.
The quarterly rate was set to missing if there were more than 6 weeks of missing diary entries during a specific quarter.
Data collected through the primary completion date are presented below.
|
Randomization through 9 Months
|
Time to First Transient Ischemic Attack (TIA)/Ischemic Stroke
Tidsramme: Randomization through 24 Months
|
Randomization through 24 Months
|
|
Number of Days Hospitalized for VOC
Tidsramme: Randomization through 24 Months
|
The total length of hospitalization in days for VOC was calculated for each participant.
Data collected through the primary completion date are presented below.
|
Randomization through 24 Months
|
Time From Randomization to First and Second VOC
Tidsramme: Randomization to First VOC and Second VOC respectively (up to 24 Months)
|
Data collected through the primary completion date are presented below.
|
Randomization to First VOC and Second VOC respectively (up to 24 Months)
|
Percentage of Participants With Hemorrhagic Events Requiring Medical Intervention
Tidsramme: First Dose through 24 Months
|
Medical intervention was defined as any medical evaluation resulting in therapy or further investigation, as determined by a trained medical professional.
Data collected from the first dose of study medication through 10 days after last dose of study medication during the double blind study period are presented below.
|
First Dose through 24 Months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 13038
- H7T-MC-TADO (Annen identifikator: Eli Lilly and Company)
- 2012-003837-41 (EudraCT-nummer)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sigdcellesykdom
-
Second Affiliated Hospital of Guangzhou Medical...Hunan Zhaotai Yongren Medical Innovation Co. Ltd.RekrutteringAnti-kreft celle immunterapi | T Cell og NK CellKina
-
Peking University People's HospitalUkjentNatural Killer Cell Medited ImmunitetKina
-
Center for International Blood and Marrow Transplant...Cellular Dynamics International, Inc. - A FUJIFILM CompanyAvsluttetiPS Cell Manufacturing and Banking
-
Medtronic - MITGAvsluttetEsophageal squamous cell neoplasia (ESCN)Kina
-
Assistance Publique - Hôpitaux de ParisHar ikke rekruttert ennå
-
Bing HanFullførtPure Red Cell Aplasia, ervervetKina
-
Debiopharm International SARekrutteringPankreas duktal adenokarsinom (PDAC) | Kolorektal kreft (CRC) | Clear Cell Renal Cell Cancer (ccRCC)Frankrike, Australia
-
Calla IVF CenterFullførtImmunmodulerende legemidler | Killer-cell immunoglobulin-lignende reseptorer (KIR) | KIR Alleles (KIR AA)Romania
-
Institute of Hematology & Blood Diseases Hospital...AvsluttetErvervet Pure Red Cell AplasiaKina
-
National Cancer Institute (NCI)RekrutteringTilbakevendende Langerhans Cell Histiocytose | Refraktær Langerhans Cell HistiocytoseForente stater, Canada
Kliniske studier på Placebo
-
SamA Pharmaceutical Co., LtdUkjentAkutt bronkitt | Akutt øvre luftveisinfeksjonKorea, Republikken
-
National Institute on Drug Abuse (NIDA)FullførtCannabisbrukForente stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyFullførtMannlige personer med type II diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedFullførtFarmakokinetikk | SikkerhetsproblemerStorbritannia
-
Texas A&M UniversityNutraboltFullførtGlucose and Insulin Response
-
Longeveron Inc.AvsluttetHypoplastisk venstre hjertesyndromForente stater
-
Regado Biosciences, Inc.FullførtFrivillig friskForente stater
-
ItalfarmacoFullførtBecker muskeldystrofiNederland, Italia
-
West Penn Allegheny Health SystemFullførtAstma | Allergisk rhinittForente stater